(Q39816545)

English

Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1 reference

based on heuristic

inferred from title

author name string

Manish Gupta

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Bei Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Timothy J Carrothers

3

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Patricia M LoRusso

4

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Yu-Waye Chu

5

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Ted Shih

6

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

David Loecke

7

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Amita Joshi

8

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Ola Saad

9

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Joo-Hee Yi

10

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sandhya Girish

11

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Clinical pharmacology in drug development

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

11-24

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Targeted cancer therapy: conferring specificity to cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Prolonged QTc interval and risk of sudden cardiac death in a population of older adults

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

A simple approach discriminating cardio-safe drugs from toxic ones

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Electrocardiographic assessment for therapeutic proteins--scientific discussion

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Drugs, hERG and sudden death

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Drug- and non-drug-associated QT interval prolongation

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

21 January 2018

QTc prolongation and sudden cardiac death: the association is in the detail

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

7 January 2021

based on heuristic

inferred from DOI database lookup

Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39816545&oldid=2090843662"